Igor S. Bazin

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Postoperative outcomes and role of adjuvant therapy in common bile duct cancer

Postoperative outcomes and role of adjuvant therapy in common bile duct cancer

Journal: Khirurgiia
Published: December 19, 2025

Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma

Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma

Journal: Khirurgiia
Published: February 04, 2025

A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.

A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.

Journal: Journal of hepatology
Published: July 26, 2024

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 24, 2020

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Journal: International journal of cancer
Published: May 17, 2017

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 22, 2016

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 29, 2015

Possibilities of stereotactic radiotherapy in the palliative treatment of patients with pancreatic cancer

Possibilities of stereotactic radiotherapy in the palliative treatment of patients with pancreatic cancer

Journal: Voprosy onkologii
Published: May 29, 2015
Showing 1-8 of 8

Last Updated: 09/26/2026